Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: SJS who wrote (227)	5/9/1998 8:11:00 AM
From: Arthur Radley	Read Replies (2) \| Respond to of 645

Sturza>>>> "....we expect the announcement of a key milestone within the next two months ....". "In June, we expect Aviron to submit a product license application for it lead product, an intranasal vaccine to prevent influenza, based on impressive Phase III clinical trial results. Of the 1,070 children receiving Aviron's vaccine in the pivotal trial, only 1% developed culture-confirmed influenza, as compared to 18% of children receiving placebo." One year target is $36.00. Looks good to me.